Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crinetics Pharmaceuticals (CRNX) Change in Accured Expenses (2017 - 2025)

Crinetics Pharmaceuticals has reported Change in Accured Expenses over the past 9 years, most recently at $11.2 million for Q4 2025.

  • Quarterly results put Change in Accured Expenses at $11.2 million for Q4 2025, up 82.73% from a year ago — trailing twelve months through Dec 2025 was $29.0 million (up 117.64% YoY), and the annual figure for FY2025 was $29.0 million, up 117.64%.
  • Change in Accured Expenses for Q4 2025 was $11.2 million at Crinetics Pharmaceuticals, up from $6.6 million in the prior quarter.
  • Over the last five years, Change in Accured Expenses for CRNX hit a ceiling of $12.5 million in Q2 2025 and a floor of -$1.4 million in Q1 2025.
  • Median Change in Accured Expenses over the past 5 years was $3.0 million (2021), compared with a mean of $3.6 million.
  • Biggest five-year swings in Change in Accured Expenses: plummeted 369.23% in 2022 and later skyrocketed 866.13% in 2025.
  • Crinetics Pharmaceuticals' Change in Accured Expenses stood at $3.9 million in 2021, then rose by 4.75% to $4.1 million in 2022, then tumbled by 53.47% to $1.9 million in 2023, then surged by 221.89% to $6.1 million in 2024, then skyrocketed by 82.73% to $11.2 million in 2025.
  • The last three reported values for Change in Accured Expenses were $11.2 million (Q4 2025), $6.6 million (Q3 2025), and $12.5 million (Q2 2025) per Business Quant data.